Your session is about to expire
← Back to Search
Pembrolizumab + Metformin for Melanoma
Study Summary
This trial will test whether adding Metformin to Pembrolizumab can help fight cancer more effectively.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
Have any preceding experiments featured Pembrolizumab Injection [Keytruda]?
"At present, there are 1126 clinical trials being conducted on Pembrolizumab Injection [Keytruda], with 165 of those studies in the advanced Phase 3 stage. Despite Houston, Texas hosting the majority of these trials, 37594 locations across the world have opened their doors to this treatment's research."
What is the current enrollment rate for this research trial?
"Affirmative. According to the clinicaltrials.gov website, this trial is currently in progress and was first posted on December 6th 2017. The most recent update was done on January 24th 2022 with a requirement of 30 participants from 1 single site."
What health conditions does Pembrolizumab Injection [Keytruda] typically address?
"The injection known as Keytruda (Pembrolizumab) is traditionally prescribed to treat unresectable melanoma. Additionally, it can be utilized in cases involving microsatellite instability high and the possibility of recurrence."
Can patients with certain conditions join this medical inquiry?
"Indeed, according to clinicaltrials.gov this research project is now open for enrollment. It was initially posted on December 6th 2017 and the details were most recently updated on January 24th 2022. 30 participants are needed from a single site in order to complete the trial successfully."
Has the FDA sanctioned Pembrolizumab Injection [Keytruda]?
"Due to the early-stage nature of this study, our team has rated Pembrolizumab Injection's [Keytruda] safety a 1. This is based on current data that only provides limited evidence for both its efficacy and security."
Share this study with friends
Copy Link
Messenger